374 related articles for article (PubMed ID: 36388082)
21. MicroRNAs in non-alcoholic fatty liver disease: Progress and perspectives.
Hochreuter MY; Dall M; Treebak JT; Barrès R
Mol Metab; 2022 Nov; 65():101581. PubMed ID: 36028120
[TBL] [Abstract][Full Text] [Related]
22. Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age?
Firneisz G
World J Gastroenterol; 2014 Jul; 20(27):9072-89. PubMed ID: 25083080
[TBL] [Abstract][Full Text] [Related]
23. Fatty Acids and Effects on In Vitro and In Vivo Models of Liver Steatosis.
Vergani L
Curr Med Chem; 2019; 26(19):3439-3456. PubMed ID: 28521680
[TBL] [Abstract][Full Text] [Related]
24. Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis.
Ooi GJ; Meikle PJ; Huynh K; Earnest A; Roberts SK; Kemp W; Parker BL; Brown W; Burton P; Watt MJ
J Hepatol; 2021 Sep; 75(3):524-535. PubMed ID: 33887358
[TBL] [Abstract][Full Text] [Related]
25. Promising therapies for treatment of nonalcoholic steatohepatitis.
Noureddin M; Zhang A; Loomba R
Expert Opin Emerg Drugs; 2016 Sep; 21(3):343-57. PubMed ID: 27501374
[TBL] [Abstract][Full Text] [Related]
26. Dysfunction of estrogen-related receptor alpha-dependent hepatic VLDL secretion contributes to sex disparity in NAFLD/NASH development.
Yang M; Liu Q; Huang T; Tan W; Qu L; Chen T; Pan H; Chen L; Liu J; Wong CW; Lu WW; Guan M
Theranostics; 2020; 10(24):10874-10891. PubMed ID: 33042259
[No Abstract] [Full Text] [Related]
27. [Role of CD36 in nonalcoholic fatty liver disease].
Zhan Z; Ren H; Peng ML
Zhonghua Gan Zang Bing Za Zhi; 2017 Dec; 25(12):953-956. PubMed ID: 29325301
[TBL] [Abstract][Full Text] [Related]
28. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
Ranjbar G; Mikhailidis DP; Sahebkar A
Metabolism; 2019 Dec; 101():154001. PubMed ID: 31672448
[TBL] [Abstract][Full Text] [Related]
29. Sorafenib reduces steatosis-induced fibrogenesis in a human 3D co-culture model of non-alcoholic fatty liver disease.
Romualdo GR; Da Silva TC; de Albuquerque Landi MF; Morais JÁ; Barbisan LF; Vinken M; Oliveira CP; Cogliati B
Environ Toxicol; 2021 Feb; 36(2):168-176. PubMed ID: 32918399
[TBL] [Abstract][Full Text] [Related]
30. Ultra-high-field magnetic resonance spectroscopy in non-alcoholic fatty liver disease: Novel mechanistic and diagnostic insights of energy metabolism in non-alcoholic steatohepatitis and advanced fibrosis.
Traussnigg S; Kienbacher C; Gajdošík M; Valkovič L; Halilbasic E; Stift J; Rechling C; Hofer H; Steindl-Munda P; Ferenci P; Wrba F; Trattnig S; Krššák M; Trauner M
Liver Int; 2017 Oct; 37(10):1544-1553. PubMed ID: 28544208
[TBL] [Abstract][Full Text] [Related]
31. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Chow MD; Lee YH; Guo GL
Mol Aspects Med; 2017 Aug; 56():34-44. PubMed ID: 28442273
[TBL] [Abstract][Full Text] [Related]
32. Foresight regarding drug candidates acting on the succinate-GPR91 signalling pathway for non-alcoholic steatohepatitis (NASH) treatment.
Liang C; Li J; Tian B; Tian L; Liu Y; Li J; Xin L; Wang J; Fu C; Shi Z; Xia J; Liang Y; Wang K
Biomed Pharmacother; 2021 Dec; 144():112298. PubMed ID: 34649219
[TBL] [Abstract][Full Text] [Related]
33. Thrombospondin 1 improves hepatic steatosis in diet-induced insulin-resistant mice and is associated with hepatic fat content in humans.
Bai J; Xia M; Xue Y; Ma F; Cui A; Sun Y; Han Y; Xu X; Zhang F; Hu Z; Liu Z; Liu Y; Cai G; Su W; Sun X; Wu H; Yan H; Chang X; Hu X; Bian H; Xia P; Gao J; Li Y; Gao X
EBioMedicine; 2020 Jul; 57():102849. PubMed ID: 32580141
[TBL] [Abstract][Full Text] [Related]
34. Potential Therapeutic Application of Estrogen in Gender Disparity of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.
Lee C; Kim J; Jung Y
Cells; 2019 Oct; 8(10):. PubMed ID: 31619023
[TBL] [Abstract][Full Text] [Related]
35. Water Extract of Dolichos lablab Attenuates Hepatic Lipid Accumulation in a Cellular Nonalcoholic Fatty Liver Disease Model.
Im AR; Kim YH; Lee HW; Song KH
J Med Food; 2016 May; 19(5):495-503. PubMed ID: 27152979
[TBL] [Abstract][Full Text] [Related]
36. Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Feng G; Li XP; Niu CY; Liu ML; Yan QQ; Fan LP; Li Y; Zhang KL; Gao J; Qian MR; He N; Mi M
Gene; 2020 Jun; 742():144549. PubMed ID: 32184169
[TBL] [Abstract][Full Text] [Related]
37. Target Deconvolution of Fenofibrate in Nonalcoholic Fatty Liver Disease Using Bioinformatics Analysis.
Mahmoudi A; Butler AE; Jamialahmadi T; Sahebkar A
Biomed Res Int; 2021; 2021():3654660. PubMed ID: 34988225
[TBL] [Abstract][Full Text] [Related]
38. Berberine Effects in Pre-Fibrotic Stages of Non-Alcoholic Fatty Liver Disease-Clinical and Pre-Clinical Overview and Systematic Review of the Literature.
Ionita-Radu F; Patoni C; Nancoff AS; Marin FS; Gaman L; Bucurica A; Socol C; Jinga M; Dutu M; Bucurica S
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673787
[TBL] [Abstract][Full Text] [Related]
39. Role of G Protein-Coupled Receptors in Hepatic Stellate Cells and Approaches to Anti-Fibrotic Treatment of Non-Alcoholic Fatty Liver Disease.
Kimura T; Singh S; Tanaka N; Umemura T
Front Endocrinol (Lausanne); 2021; 12():773432. PubMed ID: 34938271
[TBL] [Abstract][Full Text] [Related]
40. Hypoxia-inducible factor 2α drives hepatosteatosis through the fatty acid translocase CD36.
Rey E; Meléndez-Rodríguez F; Marañón P; Gil-Valle M; Carrasco AG; Torres-Capelli M; Chávez S; Del Pozo-Maroto E; Rodríguez de Cía J; Aragonés J; García-Monzón C; González-Rodríguez Á
Liver Int; 2020 Oct; 40(10):2553-2567. PubMed ID: 32432822
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
